Abstract:
FGFR3 and TP53 mutations are frequent in superficial papillary and
invasive disease, respectively. We used denaturing high-performance liq-
uid chromatography and sequencing to screen for FGFR3 and TP53
mutations in 81 newly diagnosed urothelial cell carcinomas. Tumors were
classified as follows: 31 pTa, 1 carcinoma in situ, 30 pT1, and 19 pT2-T4.
Tumor grades were as follows: 10 G1, 29 G2, and 42 G3. FGFR3 muta-
tions were associated with low-stage (P < 0.0001), low-grade (P < 0.008)
tumors, whereas TP53 mutations were associated with high-stage
(P < 0.003), high-grade (P < 0.02) tumors. Mutations in these two genes
were almost mutually exclusive. Our results suggest that FGFR3 and TP53
mutations define separate pathways at initial diagnosis of urothelial cell
carcinoma.
